semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Renal Transplant Secondary Hyperparathyroidism Males and females >18 years old Renal transplant recipients with persistent secondary hyperparathyroidism PTH persistently >80 pg/mL up 2 month post transplant (stable or progressively increasing PTH levels) No ongoing therapy with Vitamin D Patients on maintenance therapy with calcineurin inhibitors and Mycophenolate Mofetil or Azathioprine Serum creatinine < 2mg/dL Patients legally able to give written informed consent to the trial (signed and dated by the patient) Written informed consent  Concomitant administration of other forms of Vitamin D (different from paricalcitol) PTH< 80 pg/ml Serum Ca> 10,2 mg/dL Clinically serious condition History of malignancy Evidence of active hepatitis C virus, hepatitis B virus or human acquired immunodeficiency virus infection Specific contraindications or history of hypersensitivity to the study drugs Previous history of allergy or intolerance, or evidence of immunologically-mediated renal disease, systemic diseases, cancer Drug or alcohol abuse Any chronic clinical conditions that may affect completion of the trial or confound data interpretation
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Primary Hyperparathyroidism Osteopenia Osteoporosis biochemically proven PHPT, PTX planned osteopenia (t-score < -1 and > -2.5) or osteoporosis (t-score ≤ -2.5) according to WHO [27]  Premenopausal women Cancer (lung, breast, prostatic, parathyroid cancer and thyroid carcinoma >1cm) Persisting or recurrent PHPT (postoperative hypercalcemia) Four-gland hyperplasia Multiple endocrine neoplasia (MEN) or hereditary PHPT Familial hypocalciuric hypercalcaemia (Ca/creatinine ratio < 0.01) Anamnestic pulmonal embolism or deep venous thrombosis Blood coagulation disorder or coagulopathy Phenylketonuria Renal impairment (creatinine clearance <30ml/h)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-55.0,  Breast Cancer Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20. 2. Women with breast density ≥ 25% (scattered fibroglandular densities or greater) are eligible. 3. Prior Treatment 1. Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry. Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed. 2. Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry. 4. Vitamin D Use 1. Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration. 2. Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram. 5. Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible. 6. Patients with a history of breast implants or breast reduction are not eligible. 7. Patients with two or more bone fractures in the past five years are not eligible. 8. Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible. 9. Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible. 10. Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible. 11. Patients participating in a concurrent breast cancer chemoprevention trial are not eligible. 12. Required initial laboratory values Calcium < 10.5 mg/dL
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-55.0,  Abdominal Fat Body Weight Healthy subject, as determined by clinical examination, and medical history Non-menopausal woman BMI between 27 and 34 kg/m² Waist circumference > 80 cm No diet within the last 3 months with weight loss or gain not more than 3kg Non-smoking subject, or smoking less than 15 cigarettes/day since three months Normal blood pressure (BP) and heart rate (HR) after 10 minutes in supine position. Individuals values out of the normal range can be accepted if judged clinically non relevant by the investigator Laboratory parameters within the normal range of the laboratory (haematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator Subject with a habitual low (< 16 g/day) intake of whole grain foods (from cereal food intake questionnaire) willing to eat breakfast cereals  Subject having a history of metabolic disease (i.e, diabetes) Subject suffering from chronic renal insufficiency Subject receiving a local or general treatment (i.e, prescription medications, over-the-counter medications, dietary supplements or herbal supplements) susceptible to interfere with the evaluation of the studied parameters and in particular weight (eg, appetite suppressants, slimming or treatment which could interfere with the metabolism and dietary behaviour) Subject with ongoing medication not stabilized since more than 3 months Subject having had a general anaesthesia in the month preceding or gastro-intestinal surgery at any time in his/her life, with the possible exception of appendectomy Pregnant or breast-feeding subject (positive urinary pregnancy test) Subject in an period of a previous study or having participated in another clinical study in the last month Use of laxatives, except in few occasions, if, in the opinion of the investigator, does not interfere with the optimal participation Subject having received more than 4500 Euros in indemnity for participation in clinical studies in the last 12 months, including participation in the present study Subject in a situation that, in the opinion of the investigator, could interfere with his optimal participation in the study or constitute a particular risk for the subject
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Chronic Kidney Disease chronic (> 3 months) hemodialysis population of > 18 years old PTH > 300 ng/L corrected Ca > 2.10 mmol/L stable hypertensive drugs (> 1 month) stable doses of phosphate binders and dialysis calcium concentration palpable femoral pulse systolic BP of 90-180 mmHg expected survival of > 6 months  hemodialysis > 3 years acute infection history of myocardial infarction or stroke within the past 3 months inability to consent intolerance to cinacalcet inadequate birth control
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  ST-segment Elevation Myocardial Infarction Thrombus Clinical Patient is > 18 years of age Patient has ST-segment elevation of at least 0.1 mV in 2 or more contiguous leads or presumably new LBBB for all types of infarcts Patient's AMI presentation is greater than 30 minutes but less than 6 hours after symptom onset Patient provides written informed consent. Patient has no childbearing potential or is not pregnant Angiographic All patients with or without evidence of thrombus are eligible Target artery has a reference vessel diameter 2.5 mm on visual assessment at baseline angiography  Clinical Known prior history of renal insufficiency (serum creatinine 2.0 mg/dL) Cardiogenic shock Prior administration of thrombolysis for the current infarction Participation in another study Major surgery within past 6 weeks History of stroke within 30 days, or any history of hemorrhagic stroke Severe hypertension (systolic BP > 200 mm Hg or diastolic BP > 110 mm Hg) not controlled on antihypertensive therapy Known neutropenia ( <1000 neutrophils per mm3) or known severe thrombocytopenia (< 50,000 platelets per mm3) Patient unwilling to receive blood products Angiographic
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Healthy Subjects healthy subjects  pregnancy, lactation intake of dietary supplements
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pain Low Back Pain Osteoarthritis Neuropathic Pain Male or non-pregnant and non-nursing female aged 18 or older History of moderate to severe chronic pain: 1. Subjects completing study BUP-301 (low back pain) or 2. Osteoarthritis or neuropathic pain, or subjects not completing study BUP-301 (low back pain), pain for ≥3 months with a pain intensity ≥5 [11 point NRS] reported at the titration period Day 0/1 visit following a washout period (opioids, NSAIDs, and muscle relaxants) of approximately 12 to 24 hours AND currently taking ≤60 mg oral morphine equivalent/day (including opioid-naïve) for 1 week or longer Stable health, as determined by the Investigator, on the basis of medical history, physical examination, and laboratory results so as to comply with all study procedures Female subjects of childbearing potential must be using a recognized effective method of birth control Written informed consent obtained prior to any procedure being performed  Cancer related pain Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis Surgical procedure for pain within 2 months, or nerve/plexus block within 4 weeks, prior to titration period Day 0/1 visit History of severe emesis with opioids Clinically significant sleep apnea in the judgment of the investigator
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Primary Hyperparathyroidism Vitamin D Deficiency Diagnosed PHPT, defined by an elevated serum calcium level (we will not study normocalcemic PHPT) with elevated or inappropriately normal PTH levels Vitamin D3 less than 30 ng/ml  Patients with familial hyperparathyroid syndromes Current or past use of the following medications: bisphosphonate within past 2 years, use of lithium or thiazide diuretics, current use of cinacalcet, use of aluminum containing medications, cimetidine, colestipol, or orlistat Malignancy, except cured basal or squamous cell skin carcinoma or other cured cancers that are at least five years free from recurrence History or current diagnosis of certain medical diseases (including sarcoidosis, active infectious granulomatous disease, HIV/AIDS, chronic kidney disease (serum creatinine > 1.5 mg/dL), liver disease; GI diseases known to affect calcium metabolism; secondary hyperparathyroidism) We will also patients with calcium above 11.5 mg/dL, urine calcium above 350 mg/day, and active nephrolithiasis because vitamin D repletion could potentially exacerbate hypercalcemia or hypercalciuria Other exclusions protected individuals (institutionalized), prisoners, and any other prospective participant who might not be able to give voluntary informed consent
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease Men or women greater than 18 years of age The subject has voluntarily signed and dated the most recent informed consent form approved by an Institutional Review Board (IRB)  Receiving hemodialysis Receiving or has received an investigational product (or is currently using an investigational device) within 28 days prior to Visit 2 Evidence of active and clinically significant infection at Visit 2 Dental work within 48 hours prior to Visit 2
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chronic Kidney Disease Non-diabetic chronic kidney disease  Presence of DM Actively using calcium based phosphorus binder of vitamin D
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Healthy Volunteers Age 50-75 years BMI 23-30 kg/m(2) Estimated GFR >60 mL/min Blessed mental score equal to or less than 3 Ability to fully participate in an informed consent process For Trial A (UA versus Placebo): all participants should have UA<6 mg/dL For Trial B (Rasburicase versus Placebo): all participants should have UA 6.0-10 mg/dL  History of hypersensibility or intolerance to Rasburicase and/or to Lithium Chronic Kidney Disease History of kidney stones History of asthma, atopic allergies, hemolytic or methemoglobinemia reactions History of unstable angina, cardiac arrhythmia, stroke or myocardial infarction within 3 months, open-heart surgery within 6 months of the study enrollment History of drug or alcohol dependence, or positive urine toxicology Past or present positive test for HBV, HCV or HIV (base on blood test) Glucose-6-Phosphate Dehydrogenase deficiency (G6PD-deficiency) History of gout Last menstruation occurred less than 1 year ago
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 6.0-60.0,  Thalassemia Major Thalassemia Major (TM) OHD: 15-29 ng/ml Age 6 to 60 years Albumin corrected serum Calcium: Normal (8.5-10.5 mg/dl)  Other thalassemia syndromes OHD concentrations < 15 ng/ml or ≥30 ng/ml Subjects younger than 6 years Hypoparathyroidism Abnormal albumin corrected serum Ca (i.e. total calcium <8.5 or > 10.5 mg/dl) Medications that may adversely affect vitamin D metabolism (anticonvulsants) or absorption End stage renal, heart, or liver disease History of Nephrolithiasis or Nephrocalcinosis Diseases associated with hypercalciuria (ie. Sarcoidosis, Cushing syndrome, and Wilson disease to name a few)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Obesity Chronic Kidney Disease Metabolic Syndrome Group I Patients with BMI> 30 and metabolic syndrome ( ATP III). Patient with BMI> 30 without metabolic syndrome. Normal healthy control healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ). Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg) Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg) Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients CKD: nondiabetic nephropathy duration hemodialysis 3-48 months Hb-11-13 g/dl well controlled hypertension ( < 140/90 mmHg) without ACEi, ARB, allopurinol treatment residual diuresis will be estimated for last 48 hours-between mid and next dialysis  immunosuppressive agents, ACEi, ARB, allopurinol treatment diabetes mellitus not well controlled hypertension ( > 140/90 mmHg) proteinuria > 3,5 g/24 h
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 24.0-35.0,  Osteoporosis Hypercalcemia of Malignancy Hyperparathyroidism Bone Diseases, Endocrine Healthy African-American subjects of both sexes between the ages of 24-35 years, who are able to spend one week on the Clinical & Translational Research Center (CTRC) at the University of Pittsburgh Medical Center (UPMC) Montefiore  Subjects with cardiac, vascular, renal (serum creatinine > 1.5), pulmonary, endocrine, musculoskeletal, hepatic, hematologic, malignant, or rheumatologic disease will be excluded Those found to have vitamin D deficiency, defined as a 25-OH vitamin D level < 10 ng/mL will also be excluded Additionally, those with BMI > 30, anemia (hematocrit < 36% in women, <40% in men), significant alcohol use, illicit drug use, hypertension (BP>160/90), or baseline hypotension (systolic blood pressure < 90mmHg) will be excluded Those taking chronic medications (except oral contraceptive pills (OCP's) or stable doses of thyroid replacement) or those who have received an investigational drug in the past 90 days will also be excluded Prior participants in PTH or PTHrP studies will not be eligible to participate Additionally pregnant women and lactating women will be excluded; all women will have a urine pregnancy test performed immediately before starting the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 2 Diabetes Male or Female over 18 years of age Type 2 diabetes for at least 6 months Taking 1 or more oral hypoglycemic agents Patient attending your community pharmacy where you decided that addition of insulin glargine may be of benefit to the patient Baseline HbA1c 7.5 Signed informed consent  Have used, or currently using, Insulin History of ketoacidosis Pregnant Works night shift Renal impairment(Serum Creatinine: females ≥ 124 mmol/l, males ≥ 133 mmol/l) Clinically unstable Unwilling/unable to attend follow up visits Unlikely to adhere to study procedures (eg. due to cognitive limitations, severe psychiatric disorder or alcoholism)